ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Alexion to acquire autoimmune drug firm Syntimmune for up to $1.2 billion

by Ryan Cross
September 29, 2018 | APPEARED IN VOLUME 96, ISSUE 39

 

Alexion Pharmaceuticals will acquire the Boston-based biotech firm Syntimmune for $400 million plus up to $800 million in potential milestone payments. Syntimmune says its lead antibody drug candidate, SYNT001, has the potential to treat autoimmune disease by facilitating the destruction of human immunoglobulin G antibodies that cause the disease. SYNT001 is already undergoing testing in people with a rare autoimmune blistering disease called pemphigus and a rare form of autoimmune anemia.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment